Empowered Patient Podcast

Karen Jagoda
  • 4.9（16則評分）
  • 醫學
  • 每日更新
Empowered Patient Podcast

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 19 小時前 · 附贈內容

    Lab Data Insights Unlock Predictive Power to Improve Patient Care and Healthcare Efficiency with Bradley Bostic hc1 TRANSCRIPT

    Bradley Bostic, CEO of hc1, uses advanced data science, AI, and natural language processing to identify optimal patient testing, better predict disease development, and provide insights that can help prevent disease progression. The use of lab data is crucial for making diagnostic decisions, yet the potential of leveraging data is not being realized. Using technology to address issues like over-utilization of testing and data silos that prevent clinicians from seeing the complete story, hc1 is building a diagnostic insight network that unifies the provider and pharmacists to improve the patient journey and improve outcomes. Bradley explains, "We are transforming laboratories into strategic assets that improve patient care and boost the bottom line for healthcare systems. And really, the way that I came about this was having been in the healthcare industry for quite a while, most of my career, I started seeing this common fact that data was important. The largest component of the data that was used to make diagnostic decisions and diagnose patients was lab data. It's like 80% of all diagnostic decisions at least are informed by lab data. Yet, of everybody I saw out there looking to leverage data, there wasn't anybody that I saw who was hyper-specialized in how you can leverage signals from lab data to make patients healthier. I decided there was a void in the market and that we could be the best in the world. So that's what we've been working on here at hc1." "What we've been able to do is use these advanced data science capabilities, use artificial intelligence, use natural language understanding to not only be able to identify the optimal testing for patients at any given time to get to the best diagnosis faster. But also to become predictive - to identify those people in that constellation of signals who, for example, are trending toward developing chronic kidney disease or those people who are trending toward developing diabetes or any number of different disease states. We have created an artificial intelligence model that can identify individuals who are highly predisposed to developing cognitive decline well into the future without any sort of a specialized test, but just using routine test values all analyzed in this constellation."  #hc1 #HealthTechLeaders #LabData #HealthTech #HealthcareAI #HealthAI #FutureOfHealthcare #HealthcareTech #LabDiagnostics #HealthcareAnalytics hc1.com Listen to the podcast here

  2. 19 小時前

    Lab Data Insights Unlock Predictive Power to Improve Patient Care and Healthcare Efficiency with Bradley Bostic hc1

    Bradley Bostic, CEO of hc1, uses advanced data science, AI, and natural language processing to identify optimal patient testing, better predict disease development, and provide insights that can help prevent disease progression. The use of lab data is crucial for making diagnostic decisions, yet the potential of leveraging data is not being realized. Using technology to address issues like over-utilization of testing and data silos that prevent clinicians from seeing the complete story, hc1 is building a diagnostic insight network that unifies the provider and pharmacists to improve the patient journey and improve outcomes. Bradley explains, "We are transforming laboratories into strategic assets that improve patient care and boost the bottom line for healthcare systems. And really, the way that I came about this was having been in the healthcare industry for quite a while, most of my career, I started seeing this common fact that data was important. The largest component of the data that was used to make diagnostic decisions and diagnose patients was lab data. It's like 80% of all diagnostic decisions at least are informed by lab data. Yet, of everybody I saw out there looking to leverage data, there wasn't anybody that I saw who was hyper-specialized in how you can leverage signals from lab data to make patients healthier. I decided there was a void in the market and that we could be the best in the world. So that's what we've been working on here at hc1." "What we've been able to do is use these advanced data science capabilities, use artificial intelligence, use natural language understanding to not only be able to identify the optimal testing for patients at any given time to get to the best diagnosis faster. But also to become predictive - to identify those people in that constellation of signals who, for example, are trending toward developing chronic kidney disease or those people who are trending toward developing diabetes or any number of different disease states. We have created an artificial intelligence model that can identify individuals who are highly predisposed to developing cognitive decline well into the future without any sort of a specialized test, but just using routine test values all analyzed in this constellation."  #hc1 #HealthTechLeaders #LabData #HealthTech #HealthcareAI #HealthAI #FutureOfHealthcare #HealthcareTech #LabDiagnostics #HealthcareAnalytics hc1.com Download the transcript here

    24 分鐘

  3. 3 天前 · 附贈內容

    Pioneering Anti-Inflammatory Therapeutics with Dr. Niels Riedemann InflaRx TRANSCRIPT

    Niels Riedemann, the CEO, Founder, and Executive Director of the Board of InflaRx, explains that InflaRx develops pioneering anti-inflammatory therapeutics against a specific portion of the complement cascade, a part of the body’s immune system that responds to infectious microbes. By applying its proprietary monoclonal anti-C5a and anti-C5aR technologies, InflaRx hopes to affect the progression of a wide variety of inflammatory  diseases.  Niels explains, "Absolutely. So, I was a postdoc and research fellow at the University of Michigan and I researched this immune response I was talking about with another fellow in settings of sepsis of devastating, life-threatening inflammation and the other fellow and myself found it so intriguing that we ended up founding a company saying we're going to one day hopefully save people's lives with this approach by controlling this immune response. And when COVID came along, while we had a focus on other diseases and we have a key focus on devastating chronic diseases as well in the immune dermatological space and others, when COVID came along, we had all this knowledge and all this work in the immune response in life-threatening infections including in other viruses with our drug, for example, in an influenza type of virus. But we had not tested it, of course, in COVID or humans with this disease." "We felt we had to do something about it. We were very sure that this was a potential lifesaving approach. So we ended up running what we believe is the largest global study, a one-to-one randomized placebo-controlled study that was powered to show a benefit, a survival benefit, in the most severely sick COVID-patients. And when I say most severely sick, I really mean patients that need invasive mechanical ventilation or even lung replacement therapy, also called ECMO. So that's our focus, and we ended up showing a survival benefit. We may be talking about this a bit today, but it’s an interesting story and a life endeavor. I should probably also mention that in order to better understand the other side of the research part, I became a physician, and I actually ran a large academic ICU in Germany for almost seven years, and also enrolled patients in trials. So, I know how it is as an intensive care physician to take care of patients when they're that devastatingly sick. The lots of motivations within the company, and we are really glad that we could bring this drug forward to help patients." InflaRx.de Listen to the podcast here

  4. 3 天前

    Pioneering Anti-Inflammatory Therapeutics with Dr. Niels Riedemann InflaRx

    Niels Riedemann, the CEO, Founder, and Executive Director of the Board of InflaRx, explains that InflaRx develops pioneering anti-inflammatory therapeutics against a specific portion of the complement cascade, a part of the body’s immune system that responds to infectious microbes. By applying its proprietary monoclonal anti-C5a and anti-C5aR technologies, InflaRx hopes to affect the progression of a wide variety of inflammatory diseases.  Niels explains, "Absolutely. So, I was a postdoc and research fellow at the University of Michigan and I researched this immune response I was talking about with another fellow in settings of sepsis of devastating, life-threatening inflammation and the other fellow and myself found it so intriguing that we ended up founding a company saying we're going to one day hopefully save people's lives with this approach by controlling this immune response. And when COVID came along, while we had a focus on other diseases and we have a key focus on devastating chronic diseases as well in the immune dermatological space and others, when COVID came along, we had all this knowledge and all this work in the immune response in life-threatening infections including in other viruses with our drug, for example, in an influenza type of virus. But we had not tested it, of course, in COVID or humans with this disease." "We felt we had to do something about it. We were very sure that this was a potential lifesaving approach. So we ended up running what we believe is the largest global study, a one-to-one randomized placebo-controlled study that was powered to show a benefit, a survival benefit, in the most severely sick COVID-patients. And when I say most severely sick, I really mean patients that need invasive mechanical ventilation or even lung replacement therapy, also called ECMO. So that's our focus, and we ended up showing a survival benefit. We may be talking about this a bit today, but it’s an interesting story and a life endeavor. I should probably also mention that in order to better understand the other side of the research part, I became a physician, and I actually ran a large academic ICU in Germany for almost seven years, and also enrolled patients in trials. So, I know how it is as an intensive care physician to take care of patients when they're that devastatingly sick. The lots of motivations within the company, and we are really glad that we could bring this drug forward to help patients." InflaRx.de Download the transcript here

    18 分鐘

  5. 4 天前 · 附贈內容

    Tackling Emotional Barriers to Medication Adherence with Michael Oleksiw Pleio TRANSCRIPT

    Michael Oleksiw is the CEO of Pleio, a company focused on addressing the emotional barriers to patient engagement and medication adherence that medical professionals often overlook. Emotional barriers like loneliness, fear, and stigma can impact patients of all ages and backgrounds when they are facing a health challenge. Pleio uses technology and a peer-to-patient model to personalize interactions with empathetic humans, provide ongoing patient support, track emotional patterns, and bring pharmacists in to work with patients taking multiple medications or with chronic conditions.   Michael explains, "Our focus on the emotional barriers is meant to complement what’s out there today. The bulk of the focus when it comes to engaging patients and supporting patients is really on supporting the transaction, ensuring that a patient can get their medication, that they can get it cost-effectively, that they can pick it up, that it gets into their hands. But once they’re at home, everything gets real really fast and they’re faced with a variety of emotions such as loneliness, stigma, fear, etc. The American Medical Association recognizes that five of the eight major barriers to adherence are emotional, as I mentioned. So we try to stay in that swim lane and connect with the patient to target those barriers as a complement to all the stuff already being done out there." "You can say that we break White Coat syndrome in that we get the patient to focus on what’s important to them. Many times, patients don’t know or are intimidated by their healthcare professionals and don’t know how to engage in conversation. So one of the things we do is instill confidence so they can engage in fruitful conversations with their pharmacists and the like. So, the best way to think of it is we’re an extension of the pharmacy. We bring that trust and the care in the pharmacy into the home with what we call a peer-to-patient model where patients engage in conversation with people just like them to complement the baseline they received at the pharmacy." "Technology helps us be more efficient in terms of the patients we target, the words we choose, and the times we call. So, our view on technology is we use technology to support human interaction and make it better, optimize it, and make it more efficient, but not replace it. So, we don’t use technology to pretend to be human. Humans do a good job at that. I think humans could own being human. Technology is meant to support the human to be more efficient, make things more personalized, and take that step back to see the big picture and address trends over time." #Pleio #MedicationAdherence #PatientEngagement #EmotionalBarriers #MedAI #DigitalHealth pleio.com Listen to the podcast here

  6. 4 天前

    Tackling Emotional Barriers to Medication Adherence with Michael Oleksiw Pleio

    Michael Oleksiw is the CEO of Pleio, a company focused on addressing the emotional barriers to patient engagement and medication adherence that medical professionals often overlook. Emotional barriers like loneliness, fear, and stigma can impact patients of all ages and backgrounds when they are facing a health challenge. Pleio uses technology and a peer-to-patient model to personalize interactions with empathetic humans, provide ongoing patient support, track emotional patterns, and bring pharmacists in to work with patients taking multiple medications or with chronic conditions.   Michael explains, "Our focus on the emotional barriers is meant to complement what’s out there today. The bulk of the focus when it comes to engaging patients and supporting patients is really on supporting the transaction, ensuring that a patient can get their medication, that they can get it cost-effectively, that they can pick it up, that it gets into their hands. But once they’re at home, everything gets real really fast and they’re faced with a variety of emotions such as loneliness, stigma, fear, etc. The American Medical Association recognizes that five of the eight major barriers to adherence are emotional, as I mentioned. So we try to stay in that swim lane and connect with the patient to target those barriers as a complement to all the stuff already being done out there." "You can say that we break White Coat syndrome in that we get the patient to focus on what’s important to them. Many times, patients don’t know or are intimidated by their healthcare professionals and don’t know how to engage in conversation. So one of the things we do is instill confidence so they can engage in fruitful conversations with their pharmacists and the like. So, the best way to think of it is we’re an extension of the pharmacy. We bring that trust and the care in the pharmacy into the home with what we call a peer-to-patient model where patients engage in conversation with people just like them to complement the baseline they received at the pharmacy." "Technology helps us be more efficient in terms of the patients we target, the words we choose, and the times we call. So, our view on technology is we use technology to support human interaction and make it better, optimize it, and make it more efficient, but not replace it. So, we don’t use technology to pretend to be human. Humans do a good job at that. I think humans could own being human. Technology is meant to support the human to be more efficient, make things more personalized, and take that step back to see the big picture and address trends over time." #Pleio #MedicationAdherence #PatientEngagement #EmotionalBarriers #MedAI #DigitalHealth pleio.com Download the transcript here

    18 分鐘

  7. 5 天前 · 附贈內容

    EEG-Based Biomarkers for Early Detection of Neurodegenerative Diseases with Dan Levendowski and Chris Berka Advanced Brain Monitoring TRANSCRIPT

    Dan Levendowski, Co-Founder and President, and Chris Berka, Co-Founder and CEO of Advanced Brain Monitoring, have developed medical devices that measure brain activity through electroencephalography (EEG) during awake and sleeping states. These easy-to-use EEG devices can be used at home and in a clinic to identify biomarkers for cognitive decline and neurodegenerative diseases.  The company has built large databases of EEG data from healthy individuals and those with various neurodegenerative diseases, which allows them to compare a patient's brain activity to healthy controls and track changes over time.   Dan explains, "We're now in year seven of a large longitudinal study where we've identified and extracted these measures of the brain's electrical activity under different conditions that help us differentiate or characterize whether the person has normal cognition or their sleep looks like somebody with normal cognition. Or how the brain responds to certain stimuli and if it looks like somebody with Parkinson's disease or early Alzheimer's disease. We do that both during sleep and during wake."  Chris elaborates, "What differentiates our products is that Dan mentioned that we've received a little over $40 million in funding from NIH, DARPA, and other funding sources. And that has allowed us to create very large databases with tens of thousands of recordings from healthy controls. So people ages 6 to 96. For any new patient that comes in, we can compare their brain to a group of people in the same age range and sex and say, how far are you quantitatively from your healthy control peers?" "We print everything, all of the EEG sensors, on a very lightweight flex cable, which is easily applied and hits all the target sites according to the neurology 10-20 system. That is fully disposable. So after you take it off, you discard it. It's only used once. Then, all of the electronics for our system, which does the amplification of the signals, the digitization of the signals, and then sending via Bluetooth to a laptop or a handheld or desktop computer. All of that is in a very small electronics box worn on the head. The entire system weighs less than three ounces. So we've had patients wear it for many hours and forget they're wearing it. It's so lightweight and comfortable." #AdvancedBrainMonitoring #EEG #NeuroBiomarkers #Cognition #NeuroDiagnosticDevice #AlzheimersDisease #Dementia #ParkinsonsDisease #LewyBodyDementia advancedbrainmonitoring.com Listen to the podcast here

  8. 5 天前

    EEG-Based Biomarkers for Early Detection of Neurodegenerative Diseases with Dan Levendowski and Chris Berka Advanced Brain Monitoring

    Dan Levendowski, Co-Founder and President, and Chris Berka, Co-Founder and CEO of Advanced Brain Monitoring, have developed medical devices that measure brain activity through electroencephalography (EEG) during awake and sleeping states. These easy-to-use EEG devices can be used at home and in a clinic to identify biomarkers for cognitive decline and neurodegenerative diseases.  The company has built large databases of EEG data from healthy individuals and those with various neurodegenerative diseases, which allows them to compare a patient's brain activity to healthy controls and track changes over time.   Dan explains, "We're now in year seven of a large longitudinal study where we've identified and extracted these measures of the brain's electrical activity under different conditions that help us differentiate or characterize whether the person has normal cognition or their sleep looks like somebody with normal cognition. Or how the brain responds to certain stimuli and if it looks like somebody with Parkinson's disease or early Alzheimer's disease. We do that both during sleep and during wake."  Chris elaborates, "What differentiates our products is that Dan mentioned that we've received a little over $40 million in funding from NIH, DARPA, and other funding sources. And that has allowed us to create very large databases with tens of thousands of recordings from healthy controls. So people ages 6 to 96. For any new patient that comes in, we can compare their brain to a group of people in the same age range and sex and say, how far are you quantitatively from your healthy control peers?" "We print everything, all of the EEG sensors, on a very lightweight flex cable, which is easily applied and hits all the target sites according to the neurology 10-20 system. That is fully disposable. So after you take it off, you discard it. It's only used once. Then, all of the electronics for our system, which does the amplification of the signals, the digitization of the signals, and then sending via Bluetooth to a laptop or a handheld or desktop computer. All of that is in a very small electronics box worn on the head. The entire system weighs less than three ounces. So we've had patients wear it for many hours and forget they're wearing it. It's so lightweight and comfortable." #AdvancedBrainMonitoring #EEG #NeuroBiomarkers #Cognition #NeuroDiagnosticDevice #AlzheimersDisease #Dementia #ParkinsonsDisease #LewyBodyDementia advancedbrainmonitoring.com Download the transcript here

    22 分鐘
顯示全部 (2,000)

4.9
（滿分 5 顆星）
16 則評分

簡介

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

資訊

  • 創作者
    Karen Jagoda
  • 活躍年代
    2015年 - 2025年
  • 集數
    2000
  • 年齡分級
    兒少適宜
  • 版權
    © 2024
  • 節目網站
    Empowered Patient Podcast

你可能也會喜歡

若要收聽兒少不宜的單集，請登入帳號。

隨時掌握此節目最新消息

登入或註冊後，即可追蹤節目、儲存單集和掌握最新資訊。
選取國家或地區

非洲、中東和印度

亞太地區

歐洲

拉丁美洲與加勒比海地區

美國與加拿大